

Tablica 11.1. Prvih 30 lijekova po financijskoj potrošnji izraženo u eurima u 2023. godini, na teret HZZO-a

RBR	ATK	INN	UKUPNI IZNOS EUR
1	L01FF02	pembrolizumab	73.622.161
2	B01AF01	rivaroksaban	23.500.881
3	L01EL01	ibrutinib	21.098.642
4	V06DX03	namirnice za enteralnu primjenu	20.107.519
5	L02BB04	enzalutamid	18.896.213
6	L01FF01	nivolumab	17.823.760
7	L01FF05	atezolizumab	17.099.951
8	L04AA36	okrelizumab	16.609.877
9	L01FG01	bevacizumab	15.619.748
10	L01FC01	daratumumab	15.309.458
11	J06BA02	imunoglobulini, humani, za i.v. primjenu	13.818.563
12	B05AA01	albumin, ljudski	13.417.174
13	A02BC02	pantoprazol	12.736.649
14	B01AF02	apiksaban	12.541.540
15	M09AX10	risdiplam	12.336.156
16	L04AX04	lenalidomid	12.252.511
17	L01FD02	pertuzumab	12.109.084
18	A10BJ06	semaglutid	11.297.507
19	N05AX13	paliperidon	11.143.116
20	L01EF02	ribociklib	11.040.927
21	L01XX52	venetoklaks	10.842.292
22	C09DX04	valsartan i sakubitril	10.625.973
23	C10AA05	atorvastatin	10.610.037
24	R07AX32	ivakaftor, tezakaftor i eleksakaftor	10.269.677
25	L04AB02	infliksimab	10.021.180
26	L01FD01	trastuzumab	9.737.441
27	L04AB04	adalimumab	9.418.042
28	C09BX01	perindopril, amlodipin i indapamid	9.284.217
29	B05BB01	elektroliti	8.830.673
30	L01EF01	palbociklib	7.947.464